BioSpace News Archive

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced its continued support for the American Academy for Cerebral Palsy and Developmental Medicine, which will take place virtually October 6th – 9th.

Galapagos NV (Euronext & NASDAQ: GLPG) todayannouncedresults of twopost-hoc analyses from the SELECTION and SELECTION LTEstudies, which are part of the investigational clinical program for filgotinib, forthe treatment of patients with moderately to severely activeUC.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, reported the grant of non-qualified stock options to purchase an aggregate of 8,620 shares of common stock of the company and 2,880 restricted stock units of the company’s common stock to one newly hired non-executive officer employee of the company.

Augmedix, Inc. (OTCQX: AUGX), a leading provider of virtual medical documentation and live clinical support, today announced preliminary unaudited financial and operational results for the three months ended September 30, 2021.

Amgen (NASDAQ:AMGN) today announced results from real-world data in Asia, Europe, Oceania, and North and South America on the temporal trends in hip fracture incidence, and in post-fracture pharmacological treatment intervention.

Billions of dollars are spent every year because of complications of wound healing. Researchers at the College of Medicine at the University of Central Florida in Orlando have discovered a new technology to accelerate wound healing.

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the appointment of Denny Kim, M.D., MPH to the newly created role of Senior Vice President, Chief Safety Officer and Head of Global Vaccine Safety.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 40,000 shares of KalVista common stock on October 1, 2021 as inducements material to each employee entering into employment with KalVista.

Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced that it has commenced an underwritten public offering of $250 million of its common shares pursuant to its existing shelf registration statement.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced that William Ho, Chief Executive Officer and co-founder of IN8bio, will present a company overview as well as participate on an Oncology panel at BioFuture 2021.